All News
Filter News
Found 808,963 articles
-
AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020
4/16/2021
AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced strong demand for its paid tests based on the cancer differentiation analysis technology (CDA) technology, or paid CDA-based tests,
-
CRH Medical Securityholders Approve Acquisition by WELL Health
4/16/2021
CRH Medical Corporation (TSX: CRH) (NYSE: CRHM) ("CRH" or the "Company") today announced that its securityholders approved the acquisition of CRH by a subsidiary of WELL Health Technologies Corp. ("WELL Health") at the special meeting of CRH securityholders today.
-
Select Medical Holdings Corporation Announces Appointment of Katherine Davisson to its Board of Directors
4/16/2021
Select Medical Holdings Corporation ("Select Medical") (NYSE: SEM) today announced the appointment of Katherine R. Davisson to its Board of Directors (the "Board"), effective immediately.
-
Afya Limited Announces Cliquefarma’s Acquisition
4/16/2021
Afya Limited, or Afya (Nasdaq: AFYA) today announced the acquisition of 100% of the total share capital of Cliquefarma, a healthtech company operating a free-to-use website that tracks prescription drugs, cosmetics and personal hygiene product prices in Brazil
-
Stuart Therapeutics Announces Receipt of Study May Proceed Letter from U.S. FDA for ST-100 Dry Eye Disease Phase 2 Clinical Trial
4/16/2021
Stuart Therapeutics (Stuart) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of an Investigational New Drug (IND) application for Stuart's investigational product ST-100, a topical drop formulation designed to treat ocular surface diseases, including dry eye disease, an indication that affects nearly 10% of the United States population.
-
Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab
4/16/2021
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.
-
Gyroscope Therapeutics Files Registration Statement for Proposed Initial Public Offering in the United States
4/16/2021
Gyroscope Therapeutics, a clinical-stage gene therapy company focused on treating diseases of the eye, today announced it has filed a registration statement on Form F-1 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering (“IPO”) in the United States of its American Depositary Shares (“ADSs”), each representing one ordinary share.
-
CPhI Discover: pharma grows through partnering
4/16/2021
CPhI Discover (17 – 28 May 2021) is an annual online event that combines word-class content and insights with hundreds of virtual exhibitors – and will provide the industry with a new synergistic offering to sit alongside CPhI’s portfolio of in-person events.
-
Shreis Establishes Marketing and Distribution Collaborations in the US, Latin America, Mexico, and Canada for the SHYCOCAN®- A Device that Disables Coronaviruses
4/16/2021
Shreis Scalene Therapeutics LLC (SSTx), a MD-USA-based medical device company has fast-tracked the marketing and distribution of the CE-marked (EU-Class 1) Scalene Hypercharge Corona Canon (SHYCOCAN ® )
-
Synertech Medical Launches Single-Use Sterile Dural Repair Kit in the US to Improve Operating Room Efficiency
4/16/2021
Synertech, a medical device company aiming to provide simple surgical solutions, are delighted to launch their Single-use Sterile, Dural Repair Procedure Pack into the US market. During spinal surgery, especially revision surgery, the dura can become torn and a CSF leak can occur.
-
Brickell Biotech Announces Presentation of US Phase 3 Open-Label Long-Term Safety Study Results for Sofpironium Bromide Gel at the Late-Breaking Research Program during American Academy of Dermatology’s 2021 VMX
4/16/2021
Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that results from the US Phase 3
-
/R E P E A T -- Notice to the media - COVID-19 Update (April 16, 2021) - The Prime Minister, Ministers and Government of Canada officials to hold a news conference on coronavirus disease/
4/16/2021
The Prime Minister, Ministers and Government of Canada officials will hold a news conference to provide an update on coronavirus disease (COVID-19). Date April 16, 2021 Time 11:45 AM (EDT) Location Sir John A Macdonald Building, Room 200 144 Wellington Street, Ottawa, Ontario
-
Oregon Oncology Specialists Integrate AI-screening Solution VIPER™ Into Network to Expand Patient Access to Clinical Trials
4/16/2021
Deep Lens and Oregon Oncology Specialists today announced a strategic collaboration that will integrate Deep Lens’ artificial-intelligence (AI)-based clinical trial screening platform, VIPER™, into their community oncology practice network. VIPER uses proprietary cloud-based technology to facilitate, triage and accelerate the clinical trial recruitment process.
-
St. Luke's Provides Treatment for COVID 'Long Haulers'
4/16/2021
St. Luke's is pleased to introduce its new COVID Recovery Clinic, a program dedicated to the treatment of post-COVID-19 patients with lingering symptoms.
-
Ardelyx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 16, 2021
4/16/2021
Ardelyx, Inc. announced that on April 12, 2021, the compensation committee of the Company's Board of Directors granted a non-qualified stock option award to purchase 125,622 shares of its common stock and a restricted stock unit award for 26,315 shares in connection with the commencement of employment of its new Chief People Officer, Sarah O'Brien, under the Company's 2016 Employment Commencement Incentive Plan.
-
MiMedx Confirms Receipt of Director Nominations from Prescience Point Capital Management
4/16/2021
MiMedx Group, Inc. (NASDAQ: MDXG) (“MiMedx” or the “Company”), an industry leader in utilizing birth tissue as a platform for regenerative medicine, today confirmed that Prescience Point Capital Management (“Prescience Point”) submitted a notice of nomination of Eiad Asbahi, Alfred G. Merriweather, Charlotte E. Sibley and William F. Spengler
-
APEX Biologix Expands its Footprint Through Investment by Desert Highlands Regenerative
4/16/2021
Merger enables an increased focus on product innovation, more cutting-edge regenerative medicine research and strategic collaborations with other complementary technology companies.
-
HSS Study Shows Greater Increases in Training Volume Associated With Higher Risk of Injuries Among Marathon Runners
4/16/2021
New results presented at the American Medical Society for Sports Medicine 2021 Annual Meeting find runners who had more gradual increases in weekly mileage had fewer injuries
-
Aegis Life Announces Start of Phase 1/2 Trial of the Entos COVID-19 DNA Vaccine, Covigenix VAX-001, with First Participants Dosed
4/16/2021
Aegis Life, Inc. announced today that the first participants have been dosed in a Phase 1/2 clinical trial with parent company Entos Pharmaceuticals’ (Entos) Covigenix VAX-001, a novel DNA vaccine to stimulate immunity against SARS-CoV-2. Covigenix VAX-001 encodes the SARS-CoV-2 Spike (S) protein and uses novel Fusogenix technology for delivery.
-
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger
4/16/2021
Shares to commence trading on the Nasdaq Capital Market on April 19, 2021 under the new ticker symbol " MYMD " Upon Closing, the Combined Company will focus on developing and commercializing novel immunotherapy pipeline assets, including its lead molecule MYMD-1